Healthcare - Biotechnology - NASDAQ - US
$ 0.05
0 %
$ 14.1 M
Market Cap
-0.03
P/E
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.[ Read More ]
The intrinsic value of one CINGW stock under the base case scenario is HIDDEN Compared to the current market price of 0.05 USD, Cingulate Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart CINGW
FINANCIALS
0
REVENUE
-22.8 M
OPERATING INCOME
-23.5 K
NET INCOME
-15 K
OPERATING CASH FLOW
-224
INVESTING CASH FLOW
9.96 M
FINANCING CASH FLOW
0
REVENUE
-6.56 B
OPERATING INCOME
-9.41 B
NET INCOME
-14.4 B
OPERATING CASH FLOW
-13.2 M
INVESTING CASH FLOW
24.4 B
FINANCING CASH FLOW
Balance Sheet Decomposition
Cingulate Inc.
| Current Assets | 579 K |
| Cash & Short-Term Investments | 52.4 K |
| Receivables | 14.6 K |
| Other Current Assets | 512 K |
| Non-Current Assets | 2.91 M |
| Long-Term Investments | 0 |
| PP&E | 2.91 M |
| Other Non-Current Assets | 0 |
| Current Liabilities | 10.2 M |
| Accounts Payable | 5.2 M |
| Short-Term Debt | 3.38 M |
| Other Current Liabilities | 1.65 M |
| Non-Current Liabilities | 135 K |
| Long-Term Debt | 135 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Cingulate Inc.
| Revenue | 0 |
| Cost Of Revenue | 583 K |
| Gross Profit | -583 K |
| Operating Expenses | 22.8 M |
| Operating Income | -22.8 M |
| Other Expenses | -22.7 M |
| Net Income | -23.5 K |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
342.60%
ROE
-674.08%
ROA
651.33%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Cingulate Inc.
| Net Income | -23.5 K |
| Depreciation & Amortization | 583 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 813 K |
| Change in Working Capital | 7.1 M |
| Others | -5.63 M |
| Free Cash Flow | -15.3 K |
Wall Street Analysts Price Targets
Cingulate Inc.
CINGW has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Cingulate Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
Sep 15, 2023
|
Bought 3.35 K USD
|
Callahan Jennifer L.
Corporate Controller |
+ 5000
|
0.6697 USD |
|
1 year ago
Aug 11, 2023
|
Bought 1 M USD
|
Werth Peter J.
Director |
+ 1823155
|
0.5485 USD |
|
1 year ago
May 15, 2023
|
Bought 2.02 K USD
|
Callahan Jennifer L.
Corporate Controller |
+ 2000
|
1.01 USD |
|
1 year ago
May 12, 2023
|
Bought 4.32 K USD
|
Callahan Jennifer L.
Corporate Controller |
+ 4000
|
1.08 USD |
|
1 year ago
May 12, 2023
|
Bought 6.18 K USD
|
Callahan Jennifer L.
Corporate Controller |
+ 1030
|
6 USD |
|
1 year ago
Dec 16, 2022
|
Bought 52.4 USD
|
Schaffer Shane J.
Chief Executive Officer |
+ 200
|
0.262 USD |
|
1 year ago
Dec 15, 2022
|
Bought 953 USD
|
Schaffer Shane J.
Chief Executive Officer |
+ 3642
|
0.2617 USD |
|
1 year ago
Dec 16, 2022
|
Bought 10.2 K USD
|
Schaffer Shane J.
Chief Executive Officer |
+ 10000
|
1.0166 USD |
|
1 year ago
Dec 13, 2022
|
Bought 28.4 K USD
|
Werth Peter J.
Director |
+ 28934
|
0.9823 USD |
|
1 year ago
Dec 13, 2022
|
Bought 103 USD
|
Schaffer Shane J.
Chief Executive Officer |
+ 396
|
0.2593 USD |
|
1 year ago
Dec 14, 2022
|
Bought 13.4 K USD
|
Schaffer Shane J.
Chief Executive Officer |
+ 13267
|
1.01 USD |
|
1 year ago
Dec 13, 2022
|
Bought 1.75 K USD
|
Schaffer Shane J.
Chief Executive Officer |
+ 1733
|
1.01 USD |
|
1 year ago
Dec 14, 2022
|
Bought 7.47 K USD
|
Callahan Jennifer L.
Corporate Controller |
+ 7548
|
0.9894 USD |
|
1 year ago
Nov 23, 2022
|
Bought 1 K USD
|
Myers Laurie
EVP and COO |
+ 1111
|
0.8998 USD |
|
1 year ago
Nov 29, 2022
|
Bought 1.5 K USD
|
Callahan Jennifer L.
Corporate Controller |
+ 1530
|
0.98 USD |
|
1 year ago
Nov 28, 2022
|
Bought 3.42 K USD
|
Callahan Jennifer L.
Corporate Controller |
+ 3487
|
0.9798 USD |
|
1 year ago
Nov 23, 2022
|
Bought 3 K USD
|
Gilgallon Craig S.
EVP, GC and Secretary |
+ 3575
|
0.84 USD |
|
1 year ago
Nov 22, 2022
|
Bought 74.9 K USD
|
GIVENS GREGG WM
Director |
+ 85000
|
0.8806 USD |
|
2 years ago
Dec 10, 2021
|
Bought 99 K USD
|
GIVENS GREGG WM
Director |
+ 16500
|
6 USD |
|
2 years ago
Dec 10, 2021
|
Bought 49.8 K USD
|
Hargroves Thomas Jeffrey
Director |
+ 8300
|
6 USD |
|
2 years ago
Dec 10, 2021
|
Bought 99 K USD
|
Schaffer Shane J.
Chief Executive Officer |
+ 16500
|
6 USD |
|
2 years ago
Dec 10, 2021
|
Bought 49.8 K USD
|
Werth Peter J.
Director |
+ 8300
|
6 USD |
7. News
8. Profile Summary
Cingulate Inc. CINGW
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 14.1 M
Dividend Yield
0.00%
Description
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.
Contact
1901 West 47th Place, Kansas City, KS, 66205
https://www.cingulate.com
IPO Date
None
Employees
13
Officers
Dr. Matthew N. Brams M.D.
Executive Vice President & Chief Medical Officer
Dr. Raul R. Silva M.D.
Executive Vice President & Chief Science Officer
Dr. Shane J. Schaffer Pharm.D.
Chief Executive Officer & Chairman of the Board
Dr. Laurie A. Myers M.B.A., Ph.D.
Executive Vice President & Chief Operating Officer
Ms. Jennifer L. Callahan CPA
Senior Vice President, Chief Financial Officer & Secretary
Thomas Dalton
Vice President of Investor & Public Relations